Novacap SASU

Novacap SASU

Novacap SASU

Overview
Date Founded

2003

Headquarters

29, avenue Joannès Masset,Lyon, Rhone-Alpes 69009

Type of Company

Private

Industries

Chemicals
Holding Companies

Company Description

Novacap SASU manufactures and distributes chemicals for use in everyday life products. Its products include aspirin, paracetamol, sodium bicarbonate and ferric chloride. The company was founded in 2003 and is headquartered in Lyon, France.

Website
Executives & Employees

President, Chief Executive Officer & General Manager

Chief Financial Officer

General Counsel

Director, Human Resources & Administration, Secretary

Industrial Director

Strategy, M&A

Chief Executive Officer

Professional

Professional

Professional

Supervisory Board

Managing Partner & Head-Eurazeo Capital at Eurazeo SA

Managing Director at Ardian SA

General Counsel at Eurazeo SA

Executive Director, Eurazeo Capital at Eurazeo SA

Managing Director-Eurazeo Capital at Eurazeo SA

Executive Vice President & Head-Technical Operations at Merck Serono SA

Analyst at Eurazeo Capital

Independent Member-Supervisory Board at Novacap International SAS

Paths to Novacap SASU
Potential Connections via
Relationship Science
You
Novacap SASU
Recent Transactions
Details Hidden

Eurazeo SA (Private Equity), Novacap SASU purchase Produits Chimiques Auxiliaires et de Synthèse SA

Details Hidden

Ardian SA, Eurazeo SA (Private Equity), Novacap SASU, Mérieux Développement SASU purchase Chemoxy International Ltd. from Business Growth Fund Plc

Details Hidden

Eurazeo SA (Private Equity), Novacap SASU purchase Produits Chimiques Auxiliaires et de Synthèse SA

Transaction Advisors
Investment Advisor

Advised onEurazeo SA (Private Equity), Novacap SASU purchase Produits Chimiques Auxiliaires et de Synthèse SA

Investment Advisor

Advised onEurazeo SA (Private Equity), Novacap SASU purchase Produits Chimiques Auxiliaires et de Synthèse SA

Legal Advisor

Advised onNovacap SASU, Novacap International SAS purchase TaiXing YangZi Pharm Chemical Co.,Ltd.

Investment Advisor

Advised onAXA SA, Ardian SA purchase Novacap SASU from Bain Capital Private Equity LP

Founder

Advised onAXA SA, Ardian SA purchase Novacap SASU from Bain Capital Private Equity LP

Investors
Details Hidden

Eurazeo PE is a hands-on manager which follows an opportunistic, flexible investment strategy to create value in primarily private companies in continental Europe. The firm has no particular sector preferences, preferring to invest in a diverse range of industries including satellite operations, vehicle rentals and electrical equipment distribution.Eurazeo takes controlling or influential positions in profitable, well managed companies with high barriers to entry and recurring cash flow, partnering with management to enhance investee company value by supporting their strategic and capital spending decisions.The firm seeks to identify sources of value creation at an early stage to be able to have meaningful interaction with investee company managers, with whom they set up special committees whose progress is tracked by an investment team.Eurazeo focuses on companies with a value of at least €500 million, but will pursue smaller investments as long as their other investment criteria are met. From a deal flow of approximately100 per year, including spin-offs, backing of family-owned companies, secondary buyouts, privatizations or the purchase of large stakes in publicly traded companies, the firm typically invests in one to three transactions. Because Eurazeo is not an investment fund, they are able to support their investee companies over the long-term to help them complete their value-creating projects.The firm's Executive Board makes investment decisions for amounts up to €175 million. Investments of €175-€350 million require the approval of the Supervisory Board's Financial Committee.

Details Hidden

Ardian is an active manager which focuses exclusively on investing in unlisted companies and managing assets on behalf of third parties, aiming to provide long-term returns.The firm invests in buyouts of profitable high-potential companies valued between EUR 100 million and EUR 2 billion, generally taking a controlling interest, aiming to increase their growth and earnings in new markets.Ardian seeks to take controlling interests in small-cap buyouts in France, Germany and Italy, partnering with the investee company to add value and boost growth. They provide expansion capital by investing via minority interests in mature, profitable companies.Their Venture Capital team raises funds and consults innovative high-potential companies in the high-tech life sciences sector, making minority interest investments of EUR 2-5 million after receiving approval from the investment committee.They co-invest in buyout transactions involving companies valued at over EUR 500 million. The investment team constructs a diversified portfolio by sector, country, volume and type of transaction, taking minority interests in major LBOs in Europe and the US.For fund of funds, the firm performs in-house research, including track record, organization, employees and a review of individual assets in the portfolios, aiming to optimize investment in the best North American, European and Asian private equity funds.Ardian makes direct mezzanine investment in Europe as lead, co-investment and minority investor, partnering with other mezzanine funds to promote co-investment deals and increase the regional diversification of their portfolios.Their infrastructure team makes long-term investments of up to EUR 150 million in the transport, energy, water distribution and waste treatment sectors in European companies whose activity generates stable, foreseeable cash-flows.

Details Hidden

Established in 2009, Mérieux Développement is an evergreen fund specialized in the healthcare sector, conducting growth and venture capital investments worldwide. Mérieux Développement works alongside entrepreneurs whose products and services can bring genuine advances to the health of patients and consumers, offering them access to its industry expertise and global network. We invest in future leaders of the healthcare industry. We actively support those companies who create solutions to unmet needs and provide better access to high-value products and services through innovation. We are bringing our expertise and global network to enable outstanding entrepreneurs to disrupt and create new markets. Mérieux Développement is an affiliate of Institut Mérieux, which employs around 13,000 employees worldwide with consolidated revenues exceeding EUR 2.0 billion in 2013. Other companies owned by Institut Mérieux include bioMérieux (in vitro diagnostics), Mérieux NutriSciences (food safety and nutrition services) and Transgene (immunotherapy).